— Know what they know.
Not Investment Advice

SPRY NASDAQ

ARS Pharmaceuticals, Inc.
1W: +3.6% 1M: -2.0% 3M: -8.6% YTD: -28.4% 1Y: -42.6% 3Y: +0.7% 5Y: -69.0%
$7.94
-0.29 (-3.52%)
 
Weekly Expected Move ±8.3%
$6 $7 $7 $8 $9
NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 38 · $788.5M mcap · 63M float · 2.55% daily turnover · Short 64% of daily vol

Balance Sheet Trends

Total Assets
$328M -6.7% ▼
5Y CAGR: +65.5%
Total Liabilities
$213M +126.2% ▲
5Y CAGR: +39.5%
Shareholders Equity
$114M -55.5% ▼
Cash & Investments
$245M -22.0% ▼
5Y CAGR: +58.5%
Total Debt
$97M +230761.9% ▲
5Y CAGR: +57.5%
Net Debt
$56M +209.6% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$60M$211M$71M$51M$41M
Short-Term Investments$0$64M$157M$263M$204M
Cash & ST Investments$60M$274M$228M$314M$245M
Net Receivables$1K$0$795K$9M$25M
Inventory$0$0$0$5M$8M
Other Current Assets$0$1M$0$1M$6M
Total Current Assets$61M$278M$232M$334M$285M
Property, Plant & Equip.$693K$774K$824K$1M$2M
Goodwill & Intangibles$0$0$0$8M$14M
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$23K$3M$801K$8M$26M
Total Non-Current Assets$716K$4M$2M$17M$43M
Total Assets$61M$281M$233M$351M$328M
— Liabilities —
Accounts Payable$2M$2M$759K$10M$6M
Short-Term Debt$3M$0$237K$0$588K
Deferred Revenue$1M$0$0$557K$0
Other Current Liabilities$660K$1M$1M$2M$33M
Total Current Liabilities$8M$5M$2M$23M$39M
Long-Term Debt$5M$0$0$0$96M
Other Non-Current Liab.$76M$3M$0$69M$77M
Total Non-Current Liabilities$85M$3M$37K$71M$174M
Total Liabilities$93M$9M$2M$94M$213M
— Equity —
Common Stock$3K$9K$10K$10K$10K
Retained Earnings-$42M-$77M-$131M-$123M-$295M
Accumulated OCI$0$407K$49K$220K$125K
Total Stockholders Equity-$31M$273M$231M$257M$114M
Total Liabilities & Equity$61M$281M$233M$351M$328M
— Key Metrics —
Total Debt$9M$481K$274K$42K$97M
Net Debt-$51M-$210M-$71M-$51M$56M
Total Investments$0$64M$157M$263M$204M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms